Clinical Trial Results:
A 26-week, randomised, open-labelled, two-arm, parallel-group, treat-to-target trial comparing efficacy and safety of soluble insulin analogue combination (SIAC) twice daily (BID) with biphasic insulin aspart (BIAsp) 30 BID, with or without metformin, with or without DPP-4 inhibitor, with or without pioglitazone in subjects with type 2 diabetes in inadequate glycaemic control on once or twice daily premixed or self-mixed insulin regimen with or without OADs
Summary
|
|
EudraCT number |
2008-005768-15 |
Trial protocol |
SE FI |
Global completion date |
23 Aug 2010
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
30 Jan 2016
|
First version publication date |
30 Jan 2016
|
Other versions |
|
Summary report(s) |
Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.